Hydroxychloroquine sulfate
( DrugBank: Hydroxychloroquine, Hydroxychloroquine sulfate / KEGG DRUG: Hydroxychloroquine sulfate, Hydroxychloroquine, Hydroxychloroquine sulfate, Hydroxychloroquine )
4 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis | 1 |
46 | Malignant rheumatoid arthritis | 8 |
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
53 | Sjogren syndrome | 13 |
66 | IgA nephropathy | 3 |
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,543 / Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
53. Sjogren syndrome
Clinical trials : 368 / Drugs : 277 - (DrugBank : 94) / Drug target genes : 62 - Drug target pathways : 186
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
66. IgA nephropathy
Clinical trials : 349 / Drugs : 251 - (DrugBank : 75) / Drug target genes : 43 - Drug target pathways : 152
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|